Solana (HSDT) Expected to Announce Quarterly Earnings on Tuesday

Solana (NASDAQ:HSDT) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($26.50) per share and revenue of $0.14 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 4:00 PM ET.

Solana Stock Performance

Solana stock opened at $2.05 on Monday. Solana has a fifty-two week low of $1.74 and a fifty-two week high of $366.68. The company has a market capitalization of $84.46 million, a price-to-earnings ratio of 0.00 and a beta of 1.08. The stock has a fifty day moving average of $2.42 and a two-hundred day moving average of $5.86.

Institutional Trading of Solana

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC acquired a new position in Solana in the 4th quarter valued at $1,006,000. LPL Financial LLC boosted its holdings in shares of Solana by 120.1% during the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock worth $1,105,000 after purchasing an additional 208,558 shares during the last quarter. State Street Corp acquired a new stake in shares of Solana during the fourth quarter worth $464,000. Cetera Investment Advisers purchased a new stake in shares of Solana in the fourth quarter valued at $347,000. Finally, Marshall Wace LLP purchased a new stake in shares of Solana in the fourth quarter valued at $195,000. Institutional investors and hedge funds own 18.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Solana in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Solana has a consensus rating of “Sell”.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.